drugset / Trial / NCT00266877
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to learn whether HKI-272 is safe and effective in treating non-small cell lung cancer.
Timeline
- Start
- 2005-12
- Primary completion
- 2009-01
- Completion
- 2009-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Neratinib | Small molecule | 240 mg | Oral |
| Subject | Neratinib | Small molecule | 320 mg | Oral |